awmsg logo



rufinamide (Inovelon®)


Reference No. 267

Publication date:
25/11/2008


Appraisal information

rufinamide (Inovelon®) 100 mg film-coated tablet
rufinamide (Inovelon®) 200 mg film-coated tablet
rufinamide (Inovelon®) 400 mg film-coated tablet


Company: Eisai Ltd
BNF category: Central nervous system
NMG meeting date: 17/09/2008
AWMSG meeting date: 15/10/2008
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1708
Ministerial ratification: 18/11/2008

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Rufinamide (Inovelon®) is recommended for use within NHS Wales as an adjunctive therapy in patients four years and older with Lennox-Gastaut syndrome in patients where other adjunctive treatments have proved sub-optimal or have not been tolerated.
Final Appraisal Recommendation (FAR)
Download